Financial Performance - The company's operating revenue for Q3 2021 was ¥55,289,121.77, representing a year-over-year increase of 26.92%[5] - The net profit attributable to shareholders for Q3 2021 was ¥27,175,982.55, reflecting a 50.52% increase compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥22,599,759.69, showing a significant increase of 99.49% year-over-year[5] - Total revenue for the first three quarters of 2021 reached ¥151,054,585.32, a 33.6% increase compared to ¥113,069,140.66 in the same period of 2020[24] - Net profit for the third quarter of 2021 was ¥61,511,761.41, compared to ¥40,365,225.30 in the same quarter of 2020, representing a 52.3% increase[25] - The net profit attributable to the parent company shareholders for Q3 2021 was ¥61,904,233.22, an increase from ¥41,485,401.32 in Q3 2020, representing a growth of approximately 49.3%[26] - The total comprehensive income attributable to the parent company for Q3 2021 was ¥61,961,081.14, compared to ¥41,215,914.54 in Q3 2020, reflecting a growth of 50.5%[26] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥541,783,624.50, which is an 85.86% increase compared to the end of the previous year[6] - The total assets of the company as of the end of the third quarter of 2021 amounted to ¥541,783,624.50, significantly higher than ¥291,506,419.87 at the end of the same period in 2020[20] - Current assets totaled ¥347,014,032.66, compared to ¥143,318,132.92 in the previous year, indicating a substantial growth[20] - The company's total liabilities reached ¥59,635,877.98, up from ¥48,458,340.54 in the same period last year[21] - The equity attributable to shareholders increased by 97.94% year-over-year, amounting to ¥484,025,720.10[6] - The equity attributable to shareholders increased to ¥484,025,720.10 from ¥244,534,057.40 year-over-year[21] Earnings and Cash Flow - The basic earnings per share for Q3 2021 was ¥0.47, a 14.63% increase compared to the same period last year[6] - The basic and diluted earnings per share for Q3 2021 were both ¥1.24, compared to ¥0.95 in Q3 2020, indicating a year-over-year increase of 30.3%[27] - Cash flow from operating activities for the first three quarters of 2021 was ¥68,132,297.09, up from ¥38,624,149.10 in the same period of 2020, reflecting a growth of 76.4%[27] - Total cash inflow from operating activities was ¥188,256,785.37, compared to ¥137,841,460.37 in the previous year, marking an increase of 36.5%[27] - The net cash flow from financing activities for Q3 2021 was ¥183,738,361.81, a significant improvement from a net outflow of ¥3,919,836.68 in Q3 2020[28] Research and Development - Research and development expenses totaled ¥2,473,667.20 for Q3 2021, which is a decrease of 19.89% compared to the same period last year[6] - The proportion of R&D expenses to operating revenue was 4.47%, down by 2.62 percentage points year-over-year[6] - Research and development expenses for the third quarter of 2021 were ¥8,228,680.85, slightly down from ¥8,301,936.76 in the previous year[25] - The important research product, 3D printed PEEK craniofacial system, is undergoing clinical trials in five hospitals, with smooth progress in its development registration[16] Production and Operations - The new factory project for the production and research of three types of implantable medical devices is under orderly construction, with the main production and office areas completed[15] - The company has obtained the medical device production license for the new factory, which is expected to enhance production capacity and efficiency[15] - The company plans to complete the relocation to the new factory and related license changes by the end of the year[15] Revenue Breakdown - The company achieved a main business revenue of 146.91 million RMB, a year-on-year increase of 35.07%, and a net profit attributable to shareholders of 61.90 million RMB, up 49.22% year-on-year[15] - Revenue from PEEK material repair products reached 58.21 million RMB, a year-on-year growth of 70.58%[15] - The PEEK material skull fixation products generated revenue of 30.15 million RMB, reflecting a 23.80% increase compared to the same period last year[15] - The revenue from titanium skull repair products was 13.50 million RMB, showing a year-on-year growth of 16.84%[15] - The revenue from titanium skull fixation products was 38.46 million RMB, with a year-on-year increase of 5.86%[15] - The revenue from PEEK material sternum fixation system reached 3.19 million RMB, a significant increase of 1560.52% year-on-year[15]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2021 was ¥95,765,463.55, representing a year-on-year increase of 37.77% compared to ¥69,508,601.75 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥34,728,250.67, an increase of 48.22% from ¥23,430,603.89 in the previous year[19]. - The net cash flow from operating activities increased by 62.03% to ¥30,612,806.46, up from ¥18,892,747.28 in the same period last year[20]. - The total assets at the end of the reporting period were ¥542,225,029.41, reflecting an 86.01% increase from ¥291,506,419.87 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 86.84% to ¥456,896,735.67 from ¥244,534,057.40 at the end of the previous year[20]. - Basic earnings per share for the first half of 2021 were ¥0.76, a 40.74% increase from ¥0.54 in the same period last year[21]. - The company achieved a weighted average return on equity of 13.26%, an increase of 1.8 percentage points from 11.46% in the previous year[21]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and demand[1]. - New product development includes the launch of a cutting-edge titanium cranial repair product, expected to contribute an additional RMB 100 million in revenue by the end of the year[1]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors[1]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's product offerings and market share by 10%[1]. - The company aims to expand its product lines in neurosurgery and thoracic surgery while also venturing into oral and spinal fields[27]. - The company is actively developing multiple research projects, including artificial dura mater and disposable neurosurgical drainage devices, to expand its product line[52]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve operational efficiency and product quality[1]. - The research and development expenditure as a percentage of operating revenue was 6.01%, down 1.49 percentage points from 7.50% in the previous year[21]. - The company achieved a total R&D investment of ¥5,755,013.65, representing a 10.38% increase compared to the previous period's ¥5,213,960.27[43]. - The company developed a personalized skull defect repair technology using PEEK materials, enhancing customization and aesthetic outcomes compared to traditional titanium materials[40]. - The company has implemented a 3D printing technology for producing PEEK plates, which improves material efficiency and processing accuracy[40]. Risks and Challenges - No significant risks were identified during the reporting period that could impact the company's operations or financial performance[1]. - The company faces risks related to the high technical difficulty and lengthy development cycles of Class III medical devices, which could impact long-term competitiveness if registration fails[60]. - There is a risk of supply chain disruption for critical raw materials like PEEK, which could affect production and sales if suppliers cannot meet quality standards or increase prices[61]. - The penetration rate of PEEK cranial repair products is currently low in the domestic market, and any obstacles to market adoption could negatively impact sales growth[61]. - Integration risks exist following the acquisition of BIOPLATE, as effective management is crucial for maintaining operational performance and profitability[62]. Financial Position and Assets - Cash and cash equivalents at the end of the period reached ¥303,048,222.23, accounting for 55.89% of total assets, a significant increase of 226.55% compared to the previous year[75]. - The total liabilities of the company as of June 30, 2021, were RMB 87,117,450.44, compared to RMB 48,458,340.54 at the end of 2020, reflecting an increase of around 80%[178]. - The equity attributable to the parent company reached RMB 456,896,735.67, up from RMB 244,534,057.40, which is an increase of approximately 87%[178]. - The company's inventory as of June 30, 2021, was RMB 40,790,599.14, compared to RMB 36,365,569.61 at the end of 2020, showing an increase of about 12%[176]. Shareholding and Corporate Governance - The company has made commitments regarding shareholding restrictions for key personnel, including Hu Liren, who is restricted from transferring shares for 36 months post-IPO[94]. - The company will ensure compliance with regulations regarding shareholding and changes in shareholding for directors and senior management[106]. - The company has established a profit distribution policy in accordance with relevant laws and regulations, which will be strictly followed post-listing[130]. - The controlling shareholder commits to increase stock holdings according to the stock price stabilization plan after conditions are met[123]. Compliance and Environmental Responsibility - The company meets the emission standards for industrial waste gas and has proper disposal measures for hazardous waste[90]. - There have been no administrative penalties related to environmental issues during the reporting period[91]. - The company has not disclosed any additional environmental information or measures taken to reduce carbon emissions[92].